SateiaMJ, BuysseDJ, KrystalAD, et al.Clinical practice guideline for pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med, 2017; 13(2):307–349.
2.
WatersK. Review of the efficacy and safety of lemborexant, a dual receptor orexin antagonist (DORA), in the treatment of adults with insomnia disorder. Ann Pharmacother, 2022; 56(2):213–221; doi: 10.1177/10600280211008492
3.
KishiT, NishidaM, KoebisM, et al.Evidence-based insomnia treatment strategy using novel orexin antagonists: A review. Neuropsychopharmacol Rep, 2021; 41(4):450–458; doi: 10.1002/npr2.12205
4.
RochaRB, BomtempoFF, NagerGB, et al.Dual orexin receptor antagonists for the treatment of insomnia: Systematic review and network meta-analysis. Arq Neuropsiquiatr, 2023; 81(5):475–483; doi: 10.1055/s-0043-1768667
5.
AlgerSE, SteklE, Allotey-AddoS, et al.The role of pharmacological interventions for sleep deprivation and restriction. In Encyclopedia of Sleep and Circadian Rhythms. (KushidaCA., ed). 2nd ed. Academic Press; 2023:506–517. ISBN 9780323910941. doi: 10.1016/B978-0-12-822963-7.00009-8
6.
MolineM, AsakuraS, BeuckmanC, et al.The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology (Berl). 2023; 240(4):699–711; doi: 10.1007/s00213-023-06320-y
7.
ChakrabortyDS, ChoudhuryS, LahiryS. Daridorexant, a recently approved dual orexin receptor antagonist (DORA) in the treatment of insomnia. Sleep Sci, 2023; 16(2):256–264; doi: 10.1055/s-0043-1770805
8.
RosenbergR, MurphyP, ZammitG, et al.Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: A phase 3 randomized clinical trial. JAMA Netw Open, 2019; 2(12):e1918254; doi: 10.1001/jamanetworkopen.2019.18254
9.
DauvilliersY, ZammitG, FietzeI, et al.A novel dual orexin receptor antagonist (ACT-541468) to treat insomnia: A randomized, double-blind, placebo-controlled, active-reference phase 2 study. Sleep, 2019; 42(Supplement_1):A152–A153; doi: 10.1093/sleep/zsz067.374
10.
YueJL, ChangXW, ZhengJW, et al.Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis. Sleep Med Rev, 2023; 68:101746.
11.
GaoF, LiuT, TuoM, et al.The role of orexin in Alzheimer disease: From sleep-wake disturbance to therapeutic target. Neurosci Lett, 2021; 765:136247; doi: 10.1016/j.neulet.2021.136247
HerringWJ, CeesayP, SnyderE, et al.Polysomnographic assessment of suvorexant in patients with probable Alzheimer’s disease dementia and insomnia: A randomized trial. Alzheimers Dement, 2020; 16(3):541–551.
14.
HattaK, KishiY, WadaK, et al;DELIRIA-J Group. Preventive effects of suvorexant on delirium: A randomized placebo-controlled trial. J Clin Psychiatry, 2017; 78(8):e970–e979; doi: 10.4088/JCP.16m11226
15.
MatsuokaA, TobitaS, SogawaR, et al.Evaluation of suvorexant and lemborexant for the prevention of delirium in adult critically ill patients at an advanced critical care center: A single-center, retrospective, observational study. J Clin Psychiatry, 2022; 84(1):22m14471.
16.
HattaK, KishiY, WadaK, et al;Suvorexant 085 Study Group. Suvorexant for Reduction of Delirium in Older Adults After Hospitalization: A Randomized Clinical Trial. JAMA Netw Open., 2024; 7(8):e2427691; doi: 10.1001/jamanetworkopen.2024.27691
17.
XueT, WuX, ChenS, et al.The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis. Sleep Med Rev, 2022; 61:101573.
KawabeK, HoriuchiF, OchiM, et al.Suvorexant for the treatment of insomnia in adolescents. J Child Adolesc Psychopharmacol, 2017; 27(9):792–795; doi: 10.1089/cap.2017.0078
22.
WittRM, ByarsKC, DeckerK, et al.Current considerations in the diagnosis and treatment of circadian rhythm sleep-wake disorders in children. Semin Pediatr Neurol, 2023; 48:101091; doi: 10.1016/j.spen.2023.101091
